Characteristics of the study participants
| All participants (n=165) | |
|---|---|
| Demographic characteristics | |
| Age, years (SD) | 53 (13) |
| Female sex, n (%) | 127 (77) |
| Race, n (%) | |
| White | 149 (90) |
| Black | 14 (8) |
| Other | 2 (2) |
| Cancer and related therapies | |
| Cancer type, n (%) | |
| Breast cancer | 101 (61) |
| Lymphoma | 48 (29) |
| Leukaemia | 9 (6) |
| Sarcoma | 7 (4) |
| Anthracycline agent, n (%) | |
| Doxorubicin | 149 (90) |
| Other anthracycline agent | 16 (10) |
| Anthracycline dose,* mg/m2 (SD) | 240 (60) |
| Trastuzumab, n (%) | 13 (8) |
| Chest radiation therapy, n (%) | 1 (<1) |
| Prior anthracycline or chest radiation exposure, n (%) | 7 (4) |
| Medical history and risk factors | |
| Diabetes, n (%) | 18 (11) |
| Hypertension, n (%) | 52 (32) |
| Hypothyroidism, n (%) | 2 (1) |
| Hyperlipidaemia, n (%) | 33 (20) |
| Number of cardiovascular risk factors†, median (IQR) | 2 (1–3) |
| Prior cardiomyopathy, n (%) | 3 (2) |
| Current or prior tobacco use, n (%) | 70 (42) |
| Body mass index, kg/m2 (SD) | 28.4 (6.2) |
| Systolic blood pressure, mm Hg (SD) | 126 (16) |
| Diastolic blood pressure, mm Hg (SD) | 73 (10) |
| Heart rate, beats/min (SD) | 74 (13) |
| Cardiac medications, n (%) | |
| Any | 69 (42) |
| ACE inhibitor or angiotensin receptor blocker | 23 (14) |
| β blocker | 38 (23) |
| HMG-CoA reductase inhibitor | 30 (18) |
| Aspirin | 21 (13) |
*Anthracycline dose is given in doxorubicin equivalents, with doxorubicin 1 mg/m2 being considered equivalent to daunorubicin 1.0 mg/m2, epirubicin 0.67 mg/m2, idarubicin 3.0 mg/m2 and mitoxantrone 4.0 mg/m2.19
†Risk factors include history of myocardial infarction, coronary artery disease, hypertension, alcohol abuse, substance abuse, cardiomyopathy, diabetes mellitus, obesity, smoking, hypothyroidism, hyperlipidaemia, anthracycline exposure, trastuzumab exposure or radiation therapy; family history of heart disease; concurrent radiation therapy and age older than 65 years.
HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A.